Navigation Links
CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
Date:8/14/2008

- Awards recognize innovative biopharmaceutical drugs and devices that have

made a deep impact on the quality of human life -

PALO ALTO, Calif., Aug. 14 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced that its chronic angina therapy Ranexa(R) (ranolazine extended-releases tablets) has been selected as a finalist for the prestigious Prix Galien USA 2008 award which honors the best pharmaceutical agent and best biotechnology product of the year. Winners will be announced on September 24, 2008 in New York.

"Being named a finalist for the Prix Galien USA awards is a great honor. We congratulate the dedicated employees, researchers and physicians who make it possible for this important medicine to help patients every day," said Louis G. Lange, M.D., Ph.D., chairman and chief executive officer of CV Therapeutics.

The Prix Galien USA Awards committee of 11, including seven Nobel Laureates, recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines that improve the human condition, and is considered the industry's highest accolade for pharmaceutical research and development.

About Ranexa(R)

In the United Sates, Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs. In Europe, ranolazine is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Ltd. is the company's European subsidiary based in the United Kingdom.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Ranolazine is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2008. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
2. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
4. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
5. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
6. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
7. IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts
8. VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
9. CV Therapeutics Reports 2008 Second Quarter Financial Results
10. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
11. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand ... Excellence in Volunteer Experience from US2020. , US2020’s mission is to change the ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
Breaking Biology Technology:
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
Breaking Biology News(10 mins):